Mary Canning

Mary Canning has a long and varied work experience, beginning with a Medici Fellow role at the University of Nottingham in 2004. Mary then moved to Scottish Enterprise in 2005, where they served as a Senior Executive and oversaw the life science portfolio for the Proof of Concept Programme. In 2010, Mary began working at MRC Technology as a Business Manager, where they were responsible for identifying, protecting and exploiting IP. From 2013 to 2019, Mary worked at Epidarex Capital, first as a Principal and then as an Associate. Mary then moved to LUNAC Therapeutics in 2019, where they served as a Director. In 2021, Mary joined Caldan Therapeutics as a Director, and in 2022 they began working at Transine Therapeutics as a Director.

Mary Canning obtained a PhD in Molecular Genetics from The University of Edinburgh between 1996 and 2000.